2Bjornsson ES, Bergmann OM, Bjomsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425.
3Fontana RJ, Watkins PB, Bonkovsk-y HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct[J]. Drug Saf, 2009, 32(1): 55-68.
4Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug- induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966.
5Li L, Jiang W, Wang J. Clinical analysis of 275 cases of acute drug- induced liver disease[J]. Front Med China, 2007, 1(1): 58-61.
6Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug-induced liver injury[J]. Hepatology, 2013, 57(3): 873-874.
7Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Di, 2002, 22(2): 145-155.
8Bjomsson ES. Epidemiology and risk factors for idiosyncratic drug- induced liver injury[J]. Semin Liver Dis, 2014, 34(2): 115-122.
9Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes[J]. Cell Biochem Biophys, 2012, 64(2): 77-83.
10Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry[J]. Hepatology, 2006, 44(6): 1581-1588.
